COVID-19 studies are our top priority. For all other trials, there is a 4-week delay in processing a trial submitted/resubmitted to the ANZCTR and additional delays for updates of registered trials. We appreciate your patience.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12620000028909
Ethics application status
Approved
Date submitted
8/12/2019
Date registered
17/01/2020
Date last updated
17/01/2020
Date data sharing statement initially provided
17/01/2020
Type of registration
Prospectively registered

Titles & IDs
Public title
Cognitive behavioural therapy and hypnosis in the treatment of major depressive disorder: A randomised control trial
Scientific title
Cognitive behavioural therapy and hypnosis in the treatment of major depressive disorder: A randomised control trial
Secondary ID [1] 299836 0
Nil known
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Depression 315216 0
Condition category
Condition code
Mental Health 313533 313533 0 0
Depression

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment 1: cognitive behavioural therapy with hypnosis (CBTH).

Participants will receive group based therapy for 10 consecutive weeks, lasting approx. 100 minutes (plus a midway break).

Participants in this group will receive a 'therapy file' which will contain weekly handouts covering the main themes for each treatment session, group exercise worksheets and self-report sheets (e.g. activity based self-monitoring forms, thought record forms), all of which have been specifically designed for this study.

The main themes of each treatment session are:
Session 1:
Welcome
Group rules and expectations
Psycho-education on Major Depression
Group Exercise: Why change? Roadblocks to change?
Home practice task assigned

Session 2:
Review home practice Session 1
Sleep and sleep hygiene
Goal setting: Specific, Measurable, Achievable, Realistic, Time (SMART) system, graded
tasks, implementation intentions
Group exercise: goal setting for sleep
Home practice task assigned

Session 3:
Review home practice Session 2
Automaticity, routine and daily activity
Increasing self awareness
Activity Scheduling Part I: Increasing fun and pleasure
Group exercise: Goal setting for fun and pleasure
Home practice task assigned

Session 4:
Review home practice Session 3
Activity Scheduling Part II: Meaningful activity (Life Areas, Values)
Trigger Response Avoidance Patterns (TRAPs)
Group exercise: Values and TRAPs
Home practice task assigned

Session 5:
Review home practice Session 4
Avoidance, TRAPs and Functional Analysis
Trigger Response Alternative Coping (TRACs)
Group exercise: TRACs
Home practice task assigned

Session 6:
Review home practice Session 5
Midway goal review
Rumination
Rumination management: TRAC or re-focus
Group exercise: Changing rumination
Home practice task assigned

Session 7:
Review home practice Session 6
Cognitive model (ABC)
Ambiguity
Self-talk: Automatic thoughts, assumptions, beliefs
Attribution style
Group exercise: Attribution style
Home practice task assigned

Session 8:
Review home practice Session 7
Cognitive distortions
Using evidence
Behavioural experiments and surveys
Group exercise: Realistic thinking
Home practice task assigned

Session 9:
Review home practice Session 8
Problem-solving (interpersonally)
Imagery rehearsal (interpersonally)
Role playing (interpersonally)
Group exercise: Problem solving
Home practice task assigned

Session 10:
Review home practice Session 9
Review key components
Goals review
Group exercise: Insurance Policy
Group closure and farewell


The CBTH group will be given a different hypnosis based recording to listen to at the end of each session (drawing on the themes of that particular session), and at home in between sessions. These hypnosis recordings will be around 15-20 mins duration. The CBT group will be given a Progressive Muscle Relaxation recording to listen to at the end of each session, and at home in between sessions.

Home based practice will be set for all sessions and these relate to the themes covered in each session, along with listening to the recordings. Participants will be encouraged to use home based practice.

A specific CBT treatment manual will be developed for this study by the principal study investigator, who will also produce the hypnosis scripts.

The face to face treatment will be delivered to all groups by the principal investigator, who is an experienced clinical psychologist, with assistance from a co-facilitator (who will vary from group to group).

The plan is to have 5 intakes (one CBTH group and one CBT group per intake) over a period of 15 months; each intake will involve a pre-assessment and delivery of 10 weeks of consecutive treatment; each pair of intake groups will be followed up at 6 and 12 months.

All assessment and treatment will take place at the Robin Winkler Clinic, School of Psychological Science, at the University of WA.

Each intake will involve the parallel treatment of a CBTH group and CBT group, on different nights, during the same 10 week period.

Fidelity assessment will be conducted on a randomly selected number of CBTH and CBT treatment sessions.
Intervention code [1] 316089 0
Treatment: Other
Comparator / control treatment
Treatment 2: cognitive behavioural therapy group

The CBT group will receive exactly the same therapy as the CBTH group described above, except that, instead of hypnosis scripts, the CBT group will be played a recording of a Progressive Muscle Relaxation (PMR) procedure at the end of session 1, and at the end of each subsequent session. They will be instructed to listen to the recording at home, as often as possible, in between sessions.
Control group
Active

Outcomes
Primary outcome [1] 321984 0
Clinically Useful Depression Outcome Scale (CUDOS)
Timepoint [1] 321984 0
There will be 5 intakes of two groups over about 15 months. The 4 time points will vary across the 5 intakes. For example, Intake 1 the time points are show in brackets:
-Baseline (Jan/Feb 2020)
-Post-treatment (April 2020)
-6month follow-up (Oct 2020) [primary timepoint]
-12month follow-up (April 2021)
Primary outcome [2] 321985 0
Montgomery Asberg Depression Rating Scale – Clinician
Timepoint [2] 321985 0
At four time points:
-Baseline (Jan/Feb 2020)
-Post-treatment (April 2020)
-6month follow-up (Oct 2020) [primary timepoint]
-12month follow-up (April 2021)
Primary outcome [3] 321986 0
Clinically Useful Anxiety Outcome Scale (CUXOS)
Timepoint [3] 321986 0
At four time points:
-Baseline (Jan/Feb 2020)
-Post-treatment (April 2020)
-6month follow-up (Oct 2020) [primary timepoint]
-12month follow-up (April 2021)
Secondary outcome [1] 376922 0
Cognitive Behaviour Therapy Survey Questionnaire
Factor analysis shows that there are two primary factors being measured by this survey- behavioural activation and cognitive restructuring. I am interested in assessing both of these factors.
Timepoint [1] 376922 0
At 12 time points:
-Baseline (Jan/Feb 2020)
-Sessions 1-9 (Feb-Apr 2020)
-Post-treatment (April 2020)
-6month follow-up (Oct 2020) [primary time point]
-12month follow-up (April 2021)
Secondary outcome [2] 377150 0
Ruminative Response Scale- Short Form
Timepoint [2] 377150 0
At 12 time points:
-Baseline (Jan/Feb 2020)
-Sessions 1-9 (Feb-Apr 2020)
-Post-treatment (April 2020)
-6month follow-up (Oct 2020) [primary time point]
-12month follow-up (April 2021)
Secondary outcome [3] 377151 0
PROMIS Sleep Disturbance - Short Form B
Timepoint [3] 377151 0
At 12 time points:
-Baseline (Jan/Feb 2020)
-Sessions 1-9 (Feb-Apr 2020)
-Post-treatment (April 2020)
-6month follow-up (Oct 2020) [primary time point]
-12month follow-up (April 2021)
Secondary outcome [4] 377152 0
Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form
Timepoint [4] 377152 0
At four time points:
-Baseline (Jan/Feb 2020)
-Post-treatment (April 2020)
-6month follow-up (Oct 2020)
-12month follow-up (April 2021)
Secondary outcome [5] 377153 0
The Credibility/Expectancy Questionnaire
Timepoint [5] 377153 0
At baseline
Then weekly, across the 10 sessions:
-Session 1 Feb (2020) - Session 10 April (2020)
Secondary outcome [6] 377154 0
Home Practice Scale - a measure designed for this research.
The outcome being assessed is compliance.
Timepoint [6] 377154 0
Weekly, across the 10 sessions:
-Session 1 Feb (2020) - Session 10 April (2020)
Secondary outcome [7] 377955 0
Patient Health Questionnaire (PHQ-9)
Timepoint [7] 377955 0
Used as a screening questionnaire
Then weekly, across 10 sessions:
-Session 1 Feb (2020) - Session 9 April (2020)
Secondary outcome [8] 377956 0
Overall Anxiety Severity and Intensity Scale (OASIS)
Timepoint [8] 377956 0
Weekly, across the 10 sessions:
-Session 1 Feb (2020) - Session 9 April (2020)

Eligibility
Key inclusion criteria
1. Aged between 18-65 years;
2. Competency in English (both reading comprehension and written);
3. MDD diagnosed on a clinical interview using the MINI (and screened online using the PHQ-9);
4. No active suicidal ideation;
5. Does not have a disqualifying co-morbid diagnosis based on the MINI (i.e. Bi-polar Disorder, Psychosis, Personality Disorder, Alcohol/Drug Dependence, OCD or a primary Eating Disorder);
6. Is not currently receiving psychotherapy (or has in the past 12 months);
7. Can attend 10 weekly sessions during the time frame specified;
8. Is agreeable to being contacted by research assistants for telephonic and electronic based follow up assessments at 6 and 12 months post treatment;
9. Is agreeable to being randomly assigned to one of two treatment groups.

Minimum age
18 Years
Maximum age
65 Years
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Although participants may meet the inclusion criteria, they will be excluded from enrolment in the study if:
1. They do not sign consent forms;
2. They are former clients of the principal researcher/therapist.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Randomisation allocation will not be performed by the PhD investigator who is conducting this clinical trial but by a supervisor who is remotely involved. Randomisation codes will be generated electronically and then placed in sequentially numbered, sealed, opaque envelopes, to be opened at the point of randomisation (following completion of the initial assessment).
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Participant randomisation will follow CONSORT guidelines (Boutron et al. 2008) and will make use of stratification with blocking. Randomisation will be stratified by level of depression and by gender so that each treatment group (block) is approximately equivalent in terms of depression severity and gender.
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?


The people assessing the outcomes
Intervention assignment
Parallel
Other design features
Phase
Not Applicable
Type of endpoint(s)
Efficacy
Statistical methods / analysis
The aim is to enrol up to n=120 participants. Based on other MDD treatment studies, an attrition rate of 15-25% is anticipated. Alladin and Alibhai (2007) is the only published study which tested the CBT vs CBTH paradigm for MDD. A G-Power analysis was performed on their data (using a two tailed test, with a = .05 and power = .80, on the post/12mth follow up treatment effect sizes of d = .48/.22 for Mood, d = .58/.71 for Anxiety and d=.68/.53 for Hopelessness). This analysis revealed that a total sample size of 27, 18 and 12 participants would have been required at post across the three measures, and 155, 11 and 23 participants respectively at 12mth follow up. Stated differently, a general effect size of d=.29 would have been required to achieve a statistically significant result on the completed sample of 84

Statistical analyses of the primary and secondary dependent variables will be based on an intention-to-treat principle. Comparisons of CBT with CBTH at the same time intervals (weekly, then at post treatment, 6 month and 12 month follow up) will be calculated using a linear mixed-effects modelling, with restricted likelihood estimation, adjusted for baseline values of the variable under investigation.

Treatment effect sizes (Cohen’s dig) for the primary and secondary dependent variables will also be calculated and this will enable comparisons between the CBT and CBTH treatments.

Correlational analyses will be used to assess mediating and moderating variables.


Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
WA

Funding & Sponsors
Funding source category [1] 304295 0
University
Name [1] 304295 0
The University of WA
Address [1] 304295 0
35 Stirling Highway
Nedlands WA 6009
Country [1] 304295 0
Australia
Primary sponsor type
Individual
Name
Nicolino Ramondo
Address
Robin Winkler Clinic
School of Psychological Science
Myer Street
Crawley WA 6009
Country
Australia
Secondary sponsor category [1] 304540 0
Individual
Name [1] 304540 0
Dr Susan Byrne
Address [1] 304540 0
Robin Winkler Clinic
School of Psychological Science
Myer Street
Crawley WA 6009
Country [1] 304540 0
Australia

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 304751 0
The University of Western Australia Human Research Ethics Committee
Ethics committee address [1] 304751 0
University of Western Australia
35 Stirling Highway
Nedlands WA 6009
Ethics committee country [1] 304751 0
Australia
Date submitted for ethics approval [1] 304751 0
02/09/2019
Approval date [1] 304751 0
05/11/2019
Ethics approval number [1] 304751 0
RA/4/20/5703

Summary
Brief summary
The focus of this project is the treatment of adults with Major Depressive Disorder (MDD) using group psychotherapy. It will examine Cognitive Behaviour Therapy (CBT), an effective type of psychotherapy with outcomes comparable to if not better than medication. In spite of these results, only about 50% of depressed people improve with CBT, and many relapse.

Over the years, much effort has gone into exploring ways to improve treatment outcomes for MDD with CBT. Drawing on past and current research, this project combines various components of CBT into a unique and somewhat shorter treatment package.

This project aims to answer two key questions:
1. Does this 10 session CBT treatment, delivered in a group format, achieve comparable results with benchmark studies that have primarily used Behavioural Analysis, Cognitive Therapy or CBT treatment over more sessions?
2. Does CBT with the addition of hypnosis (CBTH) achieve better outcomes for MDD than CBT without hypnosis ?
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 98082 0
Mr Nicolino Ramondo
Address 98082 0
Douro House
14 Douro Place
West Perth WA 6005
Country 98082 0
Australia
Phone 98082 0
+61 8 408473362
Fax 98082 0
+61 8 93229066
Email 98082 0
nramondo@dourohouse.com.au
Contact person for public queries
Name 98083 0
Mr Nicolino Ramondo
Address 98083 0
Douro House
14 Douro Place
West Perth WA 6005
Country 98083 0
Australia
Phone 98083 0
+61 8 408473362
Fax 98083 0
+61 8 93229066
Email 98083 0
nramondo@dourohouse.com.au
Contact person for scientific queries
Name 98084 0
Mr Nicolino Ramondo
Address 98084 0
Douro House
14 Douro Place
West Perth WA 6005
Country 98084 0
Australia
Phone 98084 0
+61 8 408473362
Fax 98084 0
+61 8 93229066
Email 98084 0
nramondo@dourohouse.com.au

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
No/undecided IPD sharing reason/comment
What supporting documents are/will be available?
Study protocol
Informed consent form
Ethical approval
How or where can supporting documents be obtained?
Type [1] 5722 0
Study protocol
Citation [1] 5722 0
Link [1] 5722 0
Email [1] 5722 0
nramondo@dourohouse.com.au
Other [1] 5722 0
Attachment [1] 5722 0
Type [2] 5991 0
Informed consent form
Citation [2] 5991 0
Link [2] 5991 0
Email [2] 5991 0
nramondo@dourohouse.com.au
Other [2] 5991 0
Attachment [2] 5991 0
Type [3] 5992 0
Ethical approval
Citation [3] 5992 0
Link [3] 5992 0
Email [3] 5992 0
nramondo@dourohouse.com.au
Other [3] 5992 0
Attachment [3] 5992 0
Summary results
No Results